Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746797 · ClinicalTrials.gov registry record
Symptom Tracking in Assisted Reproductive Technologies
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 49
- Enrollment target
NCT01746797: Completed study, sponsored by Massachusetts General Hospital.
NCT01746797 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01746797 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
This study assesses risk factors for depressive relapse in women undergoing fertility treatment with histories of major depressive disorder (MDD) or bipolar disorder. The study is focused on the acute risk factors of depressive relapse. The investigators hypothesize that risk for depressive relapse will be greater among women who stop antidepressants compared to those who continue treatment with these agents.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-01-16 |
What the finished NCT01746797 record still lists
NCT01746797 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01746797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01746797 about?
NCT01746797 is a clinical study titled "Symptom Tracking in Assisted Reproductive Technologies". This study assesses risk factors for depressive relapse in women undergoing fertility treatment with histories of major depressive disorder (MDD) or bipolar disorder. The study is focused on the acute risk factors of depressive relapse. The investigators hypothesize that risk for depressive relapse...
What is the current status of trial NCT01746797?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2012-10. Estimated completion is 2018-01-16.
Who is sponsoring clinical trial NCT01746797?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia